During the public discussion of the draft law, proposals were received from the Federal Antimonopoly Service, the Federal Service for the Supervision of Public Health and Social Development, the Union of Professional Pharmaceutical Organisations, the Association of Russian Pharmaceutical Manufacturers, the Russian Homeopathic Association, the Association of International Pharmaceutical Manufacturers, and the Association of Clinical Trials Organisations, as well as a number of other organisations.
Amendments and additions are expected to be made to over 40 articles of the federal law.
The amendments will primarily affect articles on registering biological medicines and biosimilars and the interchangeability of medicine.
They will also introduce a provision on suspending the registration of medicine.
The amendment proposals have been published on the Ministry of Healthcare’s website.
